BR112022006923A2 - Polipeptídeos recombinantes para localização celular regulável - Google Patents
Polipeptídeos recombinantes para localização celular regulávelInfo
- Publication number
- BR112022006923A2 BR112022006923A2 BR112022006923A BR112022006923A BR112022006923A2 BR 112022006923 A2 BR112022006923 A2 BR 112022006923A2 BR 112022006923 A BR112022006923 A BR 112022006923A BR 112022006923 A BR112022006923 A BR 112022006923A BR 112022006923 A2 BR112022006923 A2 BR 112022006923A2
- Authority
- BR
- Brazil
- Prior art keywords
- recombinant polypeptides
- protein
- protease
- interest
- cleavage site
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000007762 localization of cell Effects 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 abstract 4
- 239000004365 Protease Substances 0.000 abstract 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 4
- 238000003776 cleavage reaction Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000007017 scission Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 230000026447 protein localization Effects 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000030570 cellular localization Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
POLIPEPTÍDEOS RECOMBINANTES PARA LOCALIZAÇÃO CELULAR REGULÁVEL. São fornecidos polipeptídeos recombinantes que compreendem uma proteína de interesse, uma etiqueta de localização de proteína e um sítio de clivagem de protease disposto entre a proteína de interesse e a etiqueta de localização de proteína. Em certas modalidades, os polipeptídeos recombinantes compreendem ainda uma protease, em que o sítio de clivagem de protease é um sítio de clivagem para a protease. Também são fornecidos ácidos nucleicos que codificam os polipeptídeos recombinantes, células que compreendem tais ácidos nucleicos e composições (por exemplo, composições farmacêuticas) que compreendem tais células. Também são fornecidos métodos de regulação da localização celular de uma proteína de interesse e métodos de administração de uma terapia regulável à base de células a um indivíduo em necessidade da mesma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962914310P | 2019-10-11 | 2019-10-11 | |
PCT/US2020/055057 WO2021072250A1 (en) | 2019-10-11 | 2020-10-09 | Recombinant polypeptides for regulatable cellular localization |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022006923A2 true BR112022006923A2 (pt) | 2022-07-05 |
Family
ID=75438153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022006923A BR112022006923A2 (pt) | 2019-10-11 | 2020-10-09 | Polipeptídeos recombinantes para localização celular regulável |
Country Status (12)
Country | Link |
---|---|
US (1) | US20240082399A1 (pt) |
EP (1) | EP4041316A4 (pt) |
JP (1) | JP2022552265A (pt) |
KR (1) | KR20220095193A (pt) |
CN (1) | CN114746126A (pt) |
AU (1) | AU2020364061A1 (pt) |
BR (1) | BR112022006923A2 (pt) |
CA (1) | CA3154218A1 (pt) |
GB (1) | GB2605514A (pt) |
IL (1) | IL292097A (pt) |
MX (1) | MX2022004410A (pt) |
WO (1) | WO2021072250A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113980143B (zh) * | 2021-11-02 | 2023-04-25 | 深圳先进技术研究院 | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005507650A (ja) * | 2001-08-01 | 2005-03-24 | セロミックス インコーポレイテッド | 新規融合タンパク質及び分子結合に関するアッセイ |
PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
WO2017004022A2 (en) * | 2015-06-29 | 2017-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
SG11201903830TA (en) * | 2016-11-22 | 2019-05-30 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
JP2020510439A (ja) * | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
AU2018313939A1 (en) * | 2017-08-10 | 2020-02-06 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof |
WO2019041296A1 (zh) * | 2017-09-01 | 2019-03-07 | 上海科技大学 | 一种碱基编辑系统及方法 |
WO2020154635A1 (en) * | 2019-01-25 | 2020-07-30 | Senti Biosciences, Inc. | Fusion constructs for controlling protein function |
-
2020
- 2020-10-09 WO PCT/US2020/055057 patent/WO2021072250A1/en unknown
- 2020-10-09 KR KR1020227015788A patent/KR20220095193A/ko unknown
- 2020-10-09 CA CA3154218A patent/CA3154218A1/en active Pending
- 2020-10-09 CN CN202080078923.2A patent/CN114746126A/zh active Pending
- 2020-10-09 MX MX2022004410A patent/MX2022004410A/es unknown
- 2020-10-09 BR BR112022006923A patent/BR112022006923A2/pt unknown
- 2020-10-09 US US17/767,818 patent/US20240082399A1/en active Pending
- 2020-10-09 EP EP20875064.6A patent/EP4041316A4/en active Pending
- 2020-10-09 JP JP2022521246A patent/JP2022552265A/ja active Pending
- 2020-10-09 GB GB2206479.4A patent/GB2605514A/en active Pending
- 2020-10-09 AU AU2020364061A patent/AU2020364061A1/en active Pending
-
2022
- 2022-04-10 IL IL292097A patent/IL292097A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20240082399A1 (en) | 2024-03-14 |
CN114746126A (zh) | 2022-07-12 |
JP2022552265A (ja) | 2022-12-15 |
KR20220095193A (ko) | 2022-07-06 |
EP4041316A4 (en) | 2023-10-11 |
WO2021072250A1 (en) | 2021-04-15 |
GB2605514A (en) | 2022-10-05 |
EP4041316A1 (en) | 2022-08-17 |
IL292097A (en) | 2022-06-01 |
GB202206479D0 (en) | 2022-06-15 |
MX2022004410A (es) | 2022-08-08 |
CA3154218A1 (en) | 2021-04-15 |
AU2020364061A1 (en) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
BR112021022874A2 (pt) | Proteínas de ligação epcam e métodos de uso | |
BR112019012964A2 (pt) | polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos | |
CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
AR020048A1 (es) | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. | |
BR112019007831A2 (pt) | ensaios in vitro e baseados em células para medição da atividade de neurotoxinas botulínicas | |
BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
BR112016002753A2 (pt) | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos | |
BR112015022440A2 (pt) | muteínas de interleucina-2 para a expansão das células t-reguladoras | |
BRPI0416258A (pt) | peptìdeos helicoidais alfa estabilizados e aplicações dos mesmos | |
BR112022004900A2 (pt) | Polipeptídeo de colágeno humano tipo 17, método para produzir o mesmo e uso do mesmo | |
MX2020003504A (es) | Receptores de celulas t que reconocen p53 mutado. | |
BR112012006501A8 (pt) | Polipeptídios e usos dos mesmos | |
BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
BR112015021993A8 (pt) | polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular | |
BR112022006923A2 (pt) | Polipeptídeos recombinantes para localização celular regulável | |
MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
CL2021000883A1 (es) | Composiciones de polipéptidos estabilizados con enlace disulfuro y métodos de uso | |
BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
BR112022005173A2 (pt) | Imunocitocina compreendendo complexo de proteína heterodimérica baseado em il-15/il-15ra, ácidos nucleicos, vetor, método célula hospedeira, composições e usos associados | |
BR112022011975A2 (pt) | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo | |
BR112015019729A2 (pt) | composição inibidora da il-1b e uso da mesma | |
BR112022009217A2 (pt) | Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos |